Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
Ceribell, Inc. (CBLL) reporting person Joseph S. Manni, Chief Revenue Officer, disclosed a sale of 660 shares of common stock on 08/25/2025 at a reported price of $11.58 per share. After the transaction he beneficially owns 27,761 shares directly. The filing indicates a routine insider sale with remaining meaningful ownership by the officer.
Ceribell, Inc. insider sale disclosed. David Foehr, Senior VP, Finance and PAO and a company officer, sold 484 shares of Ceribell common stock on 08/25/2025 at $11.58 per share. After the sale he beneficially owns 21,116 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025, documenting the transaction and reporting compliance.
Ceribell, Inc. (CBLL) reporting person Raymond Woo, Chief Technology Officer, disclosed an open-market sale of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the transaction he beneficially owned 147,704 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. No derivative transactions were reported.
Ceribell, Inc. (CBLL) director and President & CEO Jane (Xingjuan) Chao reported a sale of 2,887 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the sale, the filing shows Ms. Chao directly beneficially owns 773,135 shares. The report also discloses an indirect interest of 369,088 shares held by the ACP 2021 Trust, for which she is a co-trustee and from which she disclaims beneficial ownership except to the extent of her pecuniary interest.
The Form 4 was signed by an attorney-in-fact on 08/27/2025. The filing records a routine disposition of shares by an insider who holds substantial direct and indirect positions, and it includes the required explanatory note about the trustee relationship and disclaimer of beneficial ownership.
Ceribell, Inc. (CBLL) insider Scott Blumberg, who is Chief Financial Officer and a director, reported a disposition of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the reported sale, Mr. Blumberg beneficially owned 119,374 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. The filing lists no derivative transactions or additional explanations.
Joseph M. Taylor, a director of Ceribell, Inc. (CBLL), reported the sale of 7,032 shares of Common Stock on 08/19/2025 at a weighted-average price of $11.76. After the reported disposition, the filing shows the reporting person beneficially owned 59,235 shares. The Form 4 was filed as a single reporting-person filing and was signed by an attorney-in-fact.
CeriBell, Inc. (CBLL) Form 144: This notice reports a proposed sale of 7,032 shares of common stock through Fidelity Brokerage Services on 08/19/2025 with an aggregate market value of $82,690.42 and 36,663,968 shares outstanding. The shares were acquired via restricted stock vesting from the issuer: 414 shares vested on 06/01/2025 and 6,618 shares vested on 06/10/2025, with payment characterized as compensation. The filer states there were no securities sold in the past three months for the account reported and affirms no undisclosed material adverse information is known.